SUBSCRIBE
SUBSCRIBE

Synexa Life Sciences

Synexa Life Sciences is a biomarker and bioanalytical lab CRO, specialising in the development, validation and delivery of a wide range of complex and custom-designed assays.

With a team of over 200 staff across three global laboratory locations; Manchester, Turku (Finland) and Cape Town, we provide innovative solutions to support our customers to achieve their clinical milestones.

Our main areas of expertise include biomarker identification and development, large and small molecule clinical bioanalysis, (soluble) biomarker analysis (utilising MSD, LC-MS/MS, ELISA, RIA, fluorescence and luminescence-based technologies), cell biology (including flow cytometry, ELISpot and Fluorospot) and genomic services to support clinical trials and translational studies.

We pride ourselves on our deep scientific expertise and ability to tackle complex problems, translating them into robust and reliable assays to support clinical trial sample analysis.

NEWS
Aerial view of the coastal area of Barcelona overlooking Olympic Harbor marina
Cancer
ESMO 2024 Preview: Bispecifics and TIGITs Among the Hottest Topics in Oncology
Bispecific antibodies and anti-TIGIT therapies both appear to be writing comeback stories as cancer experts head to Barcelona for the 2024 European Society for Medical Oncology Congress. Radioligand therapies and synthetic lethality assets are also attracting attention.
September 9, 2024
 · 
4 min read
 · 
Heather McKenzie
Pictured: Collage of a dragon, congress, and money
Opinion
BIOSECURE Act Threatens Already Strained U.S. Supply Chain
As Congress considers a bill that aims to distance U.S. biopharma from five Chinese companies, the industry must emphasize the importance of prioritizing patient care over power plays.
September 9, 2024
 · 
3 min read
 · 
JX (Jaxon) Tan
AI Robot on a laptop/
Opinion
Small Biopharma Is Bringing AI Efficiency to Clinical Trials
Bringing drugs to market is notoriously time-consuming and expensive. Small companies are uniquely positioned to change that.
September 9, 2024
 · 
5 min read
 · 
Iddo Peleg
Human head with several brain visualizations
Drug Development
Late-Stage Alzheimer’s Pipeline Goes Beyond Amyloid and Tau
The next generation of Alzheimer’s therapeutics is moving away from amyloid plaques and tau tangles, offering multiple approaches to slow cognitive decline.
September 9, 2024
 · 
6 min read
 · 
Gail Dutton
Astellas Life Sciences Center in Cambridge, Mass.
Business
Astellas Pharma Opens Cambridge Life Sciences Center Featuring Incubator Space
Astellas Pharma’s new life sciences center houses its first U.S.-based SakuLab, an incubator space for external partners, as well as its engineered small molecules unit.
September 6, 2024
 · 
1 min read
 · 
Angela Gabriel
Neuron colorful watercolor vector illustration
Editorial
Roche and Sanofi MS Trials Show Potential, Challenges of Oral BTK Inhibitors
Roche’s fenebrutinib this week scored a mid-stage win in relapsing multiple sclerosis, while Sanofi’s tolebrutinib met the primary endpoint in a Phase III trial for progressive MS but flopped in two late-stage relapsing MS studies.
September 6, 2024
 · 
3 min read
 · 
Greg Slabodkin
GSK's headquarters in West London
Immunology and inflammation
GSK Builds Nucala’s COPD Case With Phase III Win
If approved in chronic obstructive pulmonary disease, Nucala will compete with Verona’s Ohtuvayre and—pending a potential approval later this month—Sanofi and Regeneron’s blockbuster Dupixent.
September 6, 2024
 · 
2 min read
 · 
Tristan Manalac
rear view businesswoman standing on wooden pier and looking to sea business and challenge crisis bankruptcy concept horizontal full length vector illustration
People
Lykos CEO to Resign After FDA Rejection of MDMA Therapy, Layoffs
Amy Emerson is stepping down on the heels of the FDA last month rejecting Lykos Therapeutics’ MDMA-based therapy for post-traumatic stress disorder and the company laying off three-quarters of its staff.
September 6, 2024
 · 
2 min read
 · 
Tristan Manalac
Pictured: FDA signage at its office in Washington, DC
Approvals
Travere Wins Full FDA Approval for IgAN Treatment Filspari
With the regulator’s traditional green light in IgA nephropathy, Filspari is up against Novartis’ Fabhalta—which won accelerated approval last month—and Calliditas’ Tarpeyo, which was approved in December 2023.
September 6, 2024
 · 
2 min read
 · 
Tristan Manalac
Load More
Visit website
Email Us
IN THE PRESS
Press Releases
Waters Sets a New Benchmark for Robustness and Sensitivity for High-Throughput Labs with the Xevo TQ Absolute XR Mass Spectrometer
June 2, 2025
 · 
4 min read
BioMidwest
Inotiv, Inc. Announces New Site Openings and Expansions Supporting Additional Capacity and Service Offerings
December 8, 2022
 · 
4 min read
Business
Parexel Announces Strategic Collaboration with Synexa Life Sciences and Drawbridge Health for COVID-19 Clinical Serology Testing Solution
November 2, 2020
 · 
4 min read
JOBS